GB201522311D0 - Use - Google Patents

Use

Info

Publication number
GB201522311D0
GB201522311D0 GBGB1522311.8A GB201522311A GB201522311D0 GB 201522311 D0 GB201522311 D0 GB 201522311D0 GB 201522311 A GB201522311 A GB 201522311A GB 201522311 D0 GB201522311 D0 GB 201522311D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522311.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Priority to GBGB1522311.8A priority Critical patent/GB201522311D0/en
Publication of GB201522311D0 publication Critical patent/GB201522311D0/en
Priority to AU2016372570A priority patent/AU2016372570B2/en
Priority to CN201680079683.1A priority patent/CN108699147B/zh
Priority to JP2018532038A priority patent/JP2018538308A/ja
Priority to PL16819062.7T priority patent/PL3390448T3/pl
Priority to CA3008548A priority patent/CA3008548A1/en
Priority to BR112018012116-9A priority patent/BR112018012116A2/en
Priority to US16/063,169 priority patent/US20180371101A1/en
Priority to RU2018124866A priority patent/RU2779543C2/ru
Priority to EP16819062.7A priority patent/EP3390448B1/en
Priority to FIEP16819062.7T priority patent/FI3390448T3/fi
Priority to PCT/EP2016/081798 priority patent/WO2017103280A1/en
Priority to ES16819062T priority patent/ES2981986T3/es
Priority to DK16819062.7T priority patent/DK3390448T3/da
Priority to KR1020187020008A priority patent/KR102878726B1/ko
Priority to US16/388,379 priority patent/US11066478B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1522311.8A 2015-12-17 2015-12-17 Use Ceased GB201522311D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
KR1020187020008A KR102878726B1 (ko) 2015-12-17 2016-12-19 방광암에 대한 방광내 요법
BR112018012116-9A BR112018012116A2 (en) 2015-12-17 2016-12-19 intravesical therapy for bladder cancer
RU2018124866A RU2779543C2 (ru) 2015-12-17 2016-12-19 Внутрипузырная терапия для рака мочевого пузыря
JP2018532038A JP2018538308A (ja) 2015-12-17 2016-12-19 膀胱癌のための膀胱内療法
PL16819062.7T PL3390448T3 (pl) 2015-12-17 2016-12-19 Terapia dopęcherzowa raka pęcherza moczowego
CA3008548A CA3008548A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer
AU2016372570A AU2016372570B2 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer
US16/063,169 US20180371101A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer
CN201680079683.1A CN108699147B (zh) 2015-12-17 2016-12-19 用于膀胱癌的膀胱内治疗
EP16819062.7A EP3390448B1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer
FIEP16819062.7T FI3390448T3 (fi) 2015-12-17 2016-12-19 Intravesikaalinen hoito virtsarakon syöpää varten
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer
ES16819062T ES2981986T3 (es) 2015-12-17 2016-12-19 Terapia intravesical para el cáncer de vejiga
DK16819062.7T DK3390448T3 (da) 2015-12-17 2016-12-19 Intravesikal terapi af blærekræft
US16/388,379 US11066478B2 (en) 2015-12-17 2019-04-18 Intravesical therapy for bladder cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use

Publications (1)

Publication Number Publication Date
GB201522311D0 true GB201522311D0 (en) 2016-02-03

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522311.8A Ceased GB201522311D0 (en) 2015-12-17 2015-12-17 Use

Country Status (14)

Country Link
US (2) US20180371101A1 (enExample)
EP (1) EP3390448B1 (enExample)
JP (1) JP2018538308A (enExample)
KR (1) KR102878726B1 (enExample)
CN (1) CN108699147B (enExample)
AU (1) AU2016372570B2 (enExample)
BR (1) BR112018012116A2 (enExample)
CA (1) CA3008548A1 (enExample)
DK (1) DK3390448T3 (enExample)
ES (1) ES2981986T3 (enExample)
FI (1) FI3390448T3 (enExample)
GB (1) GB201522311D0 (enExample)
PL (1) PL3390448T3 (enExample)
WO (1) WO2017103280A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
PH12020550124B1 (en) * 2017-12-01 2024-05-24 Nat Ct Child Health & Dev Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
AU2024231397A1 (en) 2023-03-07 2025-09-25 Photocure Asa Therapy for bladder cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291132B6 (cs) 1995-03-10 2002-12-11 Photocure Asa Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2592216T3 (es) * 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
ES2994611T3 (en) * 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
RU2018124866A3 (enExample) 2020-02-26
EP3390448B1 (en) 2024-06-05
BR112018012116A2 (en) 2018-12-04
PL3390448T3 (pl) 2024-09-16
US11066478B2 (en) 2021-07-20
AU2016372570B2 (en) 2024-01-18
CN108699147B (zh) 2022-11-01
JP2018538308A (ja) 2018-12-27
CN108699147A (zh) 2018-10-23
WO2017103280A1 (en) 2017-06-22
US20190241672A1 (en) 2019-08-08
AU2016372570A1 (en) 2018-07-12
DK3390448T3 (da) 2024-07-22
KR20180094988A (ko) 2018-08-24
RU2018124866A (ru) 2020-01-17
EP3390448A1 (en) 2018-10-24
CA3008548A1 (en) 2017-06-22
FI3390448T3 (fi) 2024-07-10
WO2017103280A9 (en) 2017-11-09
US20180371101A1 (en) 2018-12-27
ES2981986T3 (es) 2024-10-14
KR102878726B1 (ko) 2025-10-29

Similar Documents

Publication Publication Date Title
DK3256580T3 (en) Cysteinprotease
GB201502152D0 (en) Novel use
DK3298030T3 (en) Anti-cancerfusionspolypeptid
GB201509326D0 (en) Novel use
DK3390996T3 (en) Trykbart tids-temperaturindikatorsystem
GB201522309D0 (en) Use
GB201522311D0 (en) Use
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3242882T3 (en) Cgrp-antagonistpeptider
GB201521085D0 (en) Use
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201516249D0 (en) Liqui-glove
GB201518831D0 (en) New use
GB201515850D0 (en) Glycommetics
GB201522443D0 (en) Use
GB201522411D0 (en) Use
GB201515987D0 (en) Use
GB201520225D0 (en) Novel use
GB201513803D0 (en) Novel Use
GB201510628D0 (en) Novel use
GB201518560D0 (en) Unrelaxer
GB201517598D0 (en) NoFlat1
GB201515751D0 (en) DinoMania

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)